Last reviewed · How we verify
Depo-Eligard®
At a glance
| Generic name | Depo-Eligard® |
|---|---|
| Also known as | Leuprolide Acetate |
| Sponsor | Astellas Pharma Europe B.V. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
- The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer (PHASE2)
- Retrospective, Non-interventional Study of Depo-Eligard®.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |